Glaxo, Valeant face US delay for epilepsy drug

GlaxoSmithKline PLC and Valeant Pharmaceuticals International say they may have to wait an extra three months for the U.S. regulatory review of their potential epilepsy treatment ezogabine.

The two companies said Tuesday that the U.S. Food and Drug Administration has extended its target date under the Prescription Drug User Act to review ezogabine to Nov. 30 from Aug. …